Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus.
about
Incretins and selective renal sodium-glucose co-transporter 2 inhibitors in hypertension and coronary heart diseaseLinagliptin use in older individuals with type 2 diabetesTreatment intensification in patients with inadequate glycemic control on basal insulin: rationale and clinical evidence for the use of short-acting and other glucagon-like peptide-1 receptor agonistsAssessment of Saxagliptin Efficacy: Meta-Analysis of 14 Phase 2 and 3 Clinical Trials.Long-term safety and tolerability of saxagliptin add-on therapy in older patients (aged ≥ 65 years) with type 2 diabetesTrends in Antihyperglycemic Medication Prescriptions and Hypoglycemia in Older Adults: 2002-2013Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitus.Clinically relevant reductions in HbA1c without hypoglycaemia: results across four studies of saxagliptin.The dipeptidyl peptidase (DPP)-4 inhibitors for type 2 diabetes mellitus in challenging patient groups.Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences.Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation).Saxagliptin for the treatment of type 2 diabetes mellitus: focus on recent studies.Metformin + saxagliptin for type 2 diabetes.Saxagliptin: a review of its use as combination therapy in the management of type 2 diabetes mellitus in the EU.Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment.Clinical management of elderly patients with type 2 diabetes mellitus.Dipeptidyl peptidase-4 inhibitors in the elderly: more benefits or risks?Individualized treatment of type 2 diabetes mellitus using noninsulin agents: clinical considerations for the primary care physician.Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis.Meta-analysis of the cardiovascular outcomes with dipeptidyl peptidase 4 inhibitors: validation of the current FDA mandate.DPP-4 inhibitors: pharmacological differences and their clinical implications.Clinical Pharmacokinetics and Pharmacodynamics of Saxagliptin, a Dipeptidyl Peptidase-4 Inhibitor.Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials.Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis.Observational study on dipeptidyl peptidase-4 inhibitors: a real-life analysis on 360 patients from the ASL VCO territory in Italy.
P2860
Q26784211-7095C4DC-1089-410F-9A6E-93CFC4CA1E8CQ26825033-5580FD6D-8057-484F-B81E-9B77598BDE06Q28077026-6D84870B-779D-4CA9-8D37-F0AD6CC7F0A8Q33732627-0AB0D5F3-9D6B-4E47-8A5A-396870032408Q34154661-CADE6965-5FBB-4E33-9845-D7A783D56B98Q35763657-BED22ACD-3164-419F-8EA6-7BFC7AFD6844Q36785098-2013735A-D531-4F38-A2FD-28A79F2379EBQ37346737-D9268871-C635-42B6-82DF-74CE2120F9B4Q37502682-BBA111F8-B857-45DA-9FDE-DE43FF8D0D82Q37910902-B83B1384-E3DD-4C5E-970A-C59C2C1E5DC6Q37948831-9FDF736A-274C-42C7-9A6E-4F50718B853AQ37963451-A7D9E548-E364-45E3-9FF1-B9E4DBF7D5DBQ37965618-B97CD99A-7217-4379-A632-6E4F9880138AQ37973413-B630EDA4-9547-4E34-9642-46BAAF091C76Q37982112-002DBCF0-A392-4F5B-9096-BF9DC6F2F598Q37982214-E22EEA93-4F10-4A58-99CA-861A939D4324Q37992956-29885D54-03C6-4B49-A6AE-D5BF19AC2246Q38036773-C0124A15-D1B4-4C49-92B1-571CDE99DDD5Q38101993-7004298F-DAED-46C3-AB66-695D2CECF146Q38200923-4B203937-423D-4FC0-A734-363266BA855CQ38244576-51803C14-21CF-4B42-8F59-51A56CD39DC2Q38860371-41FA2FEC-F890-4684-AE35-38EEE0E34F5CQ44143356-0F488DE5-9463-473A-8BDC-60C19459C1C4Q50876480-0712B2F9-BA5A-4ADA-BC0E-707C41F77A03Q51323275-CFBAC08B-8CE0-453E-9153-60A8DA475105
P2860
Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus.
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus.
@ast
Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus.
@en
Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus.
@nl
type
label
Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus.
@ast
Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus.
@en
Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus.
@nl
prefLabel
Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus.
@ast
Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus.
@en
Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus.
@nl
P2093
P1476
Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus.
@en
P2093
Antonio Chacra
Jean Doucet
Pierre Maheux
Susan Harris
P304
P356
10.1185/03007995.2011.554532
P407
P577
2011-02-17T00:00:00Z